• 4 August 2015
    JenaValve appoints Peter C. Wulff as Chief Financial Officer

    JenaValve Technology, Inc., a developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical technology financial executive Peter C. Wulff as Chief Financial Officer (CFO), effective immediately. Mr. Wulff will be based in Irvine, Calif. at JenaValve’s new corporate headquarters. “

    “With more than two decades of financial and operations management experience in life science companies, we are confident that Mr. Wulff will have a significant impact on JenaValve and be a key contributor to our future. Peter is joining an experienced global team that is committed to positioning JenaValve to compete on the world TAVR stage,” said CEO Victoria E. Carr-Brendel, Ph.D.

    “I look forward to working with Dr. Carr-Brendel, her highly capable management team and the committed board of directors at JenaValve. I understand the challenges ahead and believe that solid leadership combined with the unique valve technology, will indeed grow JenaValve into becoming a major player in TAVR market,” said Mr. Wulff.

    Mr. Wulff brings more than 25 years of broad corporate finance and accounting experience to JenaValve, including more than 15 years in chief financial officer roles at publicly traded and privately-held life sciences companies. His industry experience includes CFO positions at medical technology companies Alphatec Spine, Inc., Artes Medical, Inc., and CryoCor, Inc. Most recently, Mr. Wulff served as CFO and COO for Pure Biosciences, Inc. Mr. Wulff earned an M.B.A. in Finance and a bachelor’s degree in Economics and Germanic Languages, each from Indiana University.

    Dr. Carr-Brendel stated further, “JenaValve is currently focused on gaining regulatory approval to begin our clinical study employing our latest Transapical and Transfemoral systems designed to capitalize on our years of TAVR experience. We are encouraged by the strength of the TAVR market driven by continued strong outcome data including treatment of moderate risk patients and are confident that with our differentiated technology platform we can gain significant share in this market in the years ahead.”